Results 11 to 20 of about 6,511 (194)
Long-Term Results of Cabergoline Add-on Long-Acting Somatostatin Analogue Therapy in Acromegaly Patients [PDF]
Gazi Medical JournalObjective: To investigate the efficacy of the dopamine agonist cabergoline in uncontrolled acromegaly despite long-acting somatostatin analog (SSA). Methods: Thirty-five patients with acromegaly who were followed up in the department of endocrinology ...
Mehmet Muhittin Yalçın +13 more
doaj +2 more sources
Cabergoline therapy for Macroprolactinoma during pregnancy: A case report
BMC Research Notes, 2012 Background We assessed the safety of Cabergoline therapy during pregnancy in a lady with hyperprolactinemia intolerant to Bromocriptine. Case presentation We report the case of a 31 year old lady who presented to us with uncontrolled hyperprolactinemia ...
Shahzad Hira +2 more
doaj +3 more sources
Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma
Indian Journal of Endocrinology and Metabolism, 2017 Background: Clinical relevance of association of cabergoline use for hyperprolactinemia and cardiac valvulopathy remains unclear. Objective: The aim of the study was to determine the prevalence of valvular heart abnormalities in patients taking ...
Shruti Khare +6 more
doaj +2 more sources
Cabergoline in the Treatment of Male Orgasmic Disorder—A Retrospective Pilot Analysis
Sexual Medicine, 2016 Introduction: Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction.
Adam B. Hollander, MD +6 more
doaj +3 more sources
Journal of Pharmacological Sciences, 2006 .: Cabergoline is used in the treatment of Parkinson’s disease (PD). Clarithromycin is a potent inhibitor of CYP3A4 and P-glycoprotein and is often co-administered with cabergoline in usual clinical practice.
Masahiro Nagai +2 more
exaly +3 more sources
Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. [PDF]
PLoS ONE, 2014 Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases.
Haruki Odaka +7 more
doaj +2 more sources
Place of Cabergoline in Acromegaly: A Meta-Analysis
Journal of Clinical Endocrinology and Metabolism, 2011 Context: Cabergoline is widely considered to be poorly effective in acromegaly. Objective: The aim of this study was to obtain a more accurate ...
Patrick Maison +2 more
exaly +2 more sources
Cabergoline-induced tricuspid regurgitation: Case report and review of literature
Indian Journal of Endocrinology and Metabolism, 2011 The increased risk of cardiac valve disease in patients treated for Parkinson′s disease with cabergoline has raised concerns about the safety of treatment with ergot-derived dopamine agonists in patients with endocrine diseases, especially prolactinoma ...
Mohammad Hayat Bhat +4 more
doaj +2 more sources
Biological Psychiatry, 2009 Background: Cabergoline is an ergotamine derivative that increases the expression of glial cell line-derived neurotrophic factor (GDNF) in vitro. We recently showed that GDNF in the ventral tegmental area (VTA) reduces the motivation to consume alcohol ...
Sébastien Carnicella +2 more
exaly +2 more sources
Cabergoline-induced mania in a patient of pituitary microadenoma
Indian Journal of Psychological Medicine, 2017 Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj +2 more sources